Matinas BioPharma Holdings, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
Matinas BioPharma Holdings filed a Form 8-K on November 3, 2026 reporting Item 8.01 (Other Events). The filing document does not contain the substantive text of the disclosure—only metadata showing the filing was accepted and XBRL formatted data files were submitted. No specific counterparties, dollar amounts, share counts, dates, or business developments are disclosed in the accessible filing text.
Why this rating
Filing itself is routine administrative disclosure; content unknown. At $4.5M market cap, material news would be disclosed; absence suggests routine matter.
Extracted items
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.